HRP20231241T1 - Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa - Google Patents
Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa Download PDFInfo
- Publication number
- HRP20231241T1 HRP20231241T1 HRP20231241TT HRP20231241T HRP20231241T1 HR P20231241 T1 HRP20231241 T1 HR P20231241T1 HR P20231241T T HRP20231241T T HR P20231241TT HR P20231241 T HRP20231241 T HR P20231241T HR P20231241 T1 HRP20231241 T1 HR P20231241T1
- Authority
- HR
- Croatia
- Prior art keywords
- grade
- composition
- use according
- rtog
- ctcae
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 18
- 230000000699 topical effect Effects 0.000 title claims 9
- 229940125431 BRAF inhibitor Drugs 0.000 title claims 6
- 208000006934 radiodermatitis Diseases 0.000 title claims 3
- -1 ARQ680 Chemical compound 0.000 claims 18
- 206010067484 Adverse reaction Diseases 0.000 claims 12
- 230000006838 adverse reaction Effects 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical group C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 claims 2
- 101150009274 nhr-1 gene Proteins 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 claims 1
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims 1
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 claims 1
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Sastav za lokalnu primjenu koji sadrži terapeutski i/ili profilaktički učinkovitu dozu najmanje jednog BRaf inhibitora ili njihove kombinacije i farmaceutski prihvatljivog nosača ili pomoćne tvari za upotrebu u liječenju, prevenciji ili ublažavanju radijacijskog dermatitisa lokalnom primjenom subjektu kojem je to potrebno,
pri čemu je navedeni najmanje jedan BRaf inhibitor odabran između BAY43-9006 (Sorafenib), LGX818 (enkorafenib), PLX4032 (vemurafenib), GSK2118436 (dabrafenib), ARQ736, ARQ680, AZ628, C-I, C-15, C-19, C-A, CEP-32496, GDC-0879, NMS-P186, NMS-P349, NMS-P383, NMS-P396, NMS-P730, PLX3603 (RO5212054), PLX4720 (difluorofenil-sulfonamin), PF-04880594, PLX4734, RAF265,
R04987655, SB590885, ZM336372, BMS908662, WYE-130600, TAK632, MLN 2480, XL281,
spoj formule (I):
[image]
pri čemu je R odabran iz skupine koju čine p-klorofenil, 3-etinilfenil, 3-kloro-4-fluorofenil, 2-fluoro-4-jodofenil, 4-kloro-3-(trifluorometil)fenil, 3-(1, 1-dimetiletil)-1-metil-1H-pirazol-5-il, 3-(trifluorometoksi)fenil, 3,5-dihidroksifenil, fenil-3-sulfonamid ili 3-(trifluorometil)fenil, ili farmaceutski prihvatljiva sol ili njegov solvat;
spoj formule (II):
[image]
pri čemu R je NHR1, pri čemu je R1 2-fluoro-4-jodofenil, ili njegova farmaceutski prihvatljiva sol ili solvat;
spoj formule (III):
[image]
pri čemu je R NHR1, pri čemu je R1 3-etinilfenil, 3-kloro-4-fluorofenil, 2-fluoro-4-jodofenil ili 4-kloro 3-(trifluorometil) fenil, ili njegova farmaceutski prihvatljiva sol ili solvat;
ili njihovu kombinaciju; i farmaceutski prihvatljiv nosač ili pomoćna tvar.
2. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 1, pri čemu je BRaf inhibitor spoj formule (I) i pri čemu je R 3-(trifluorometoksi)fenil.
3. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 2, pri čemu je sastav u obliku gela, hidrogela, masti, kreme, paste, pjene, spreja, losiona, tekućine ili dermalnog flastera.
4. Sastav za lokalnu primjenu za upotrebu prema bilo kojem patentnom zahtjevu 1-3, pri čemu je BRaf inhibitor prisutan u sastavu u koncentraciji od 1% masenog udjela do 5% masenog udjela od ukupne mase sastava.
5. Sastav za lokalnu primjenu za upotrebu prema bilo kojem patentnom zahtjevu 1-3, pri čemu je BRaf inhibitor prisutan u sastavu u koncentraciji od 0.1% masenog udjela do 10% masenog udjela od ukupne mase sastava.
6. Sastav za lokalnu primjenu za upotrebu prema bilo kojem patentnom zahtjevu 1-5, pri čemu upotreba smanjuje ozbiljnost ili sprječava eskalaciju radijacijskog dermatitisa.
7. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 6, pri čemu upotreba smanjuje ozbiljnost kožne nuspojave sa stupnja 4 na stupanj 3, 2, 1 ili 0 kako je definirano Zajedničkim terminološkim kriterijima za nuspojave Nacionalnog instituta za rak (NCI-CTCAE) verzije 5.0 ili prema ljestvici ocjenjivanja Onkološke grupe za radijacijsku terapiju (RTOG).
8. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 6, pri čemu upotreba smanjuje ozbiljnost kožne nuspojave sa stupnja 3 na stupanj 2, 1 ili 0, kako je definirano Zajedničkim terminološkim kriterijima za nuspojave Nacionalnog instituta za rak (NCI-CTCAE) verzije 5.0 ili odgovarajućom RTOG ocjenom.
9. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 6, pri čemu upotreba smanjuje ozbiljnost kožne nuspojave sa stupnja 2 na stupanj 1 ili 0, kako je definirano Zajedničkim terminološkim kriterijima za nuspojave Nacionalnog instituta za rak (NCI-CTCAE) verzije 5.0 ili odgovarajućom RTOG ocjenom.
10. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 6, pri čemu upotreba smanjuje ozbiljnost kožne nuspojave sa stupnja 1 na stupanj 0, kako je definirano Zajedničkim terminološkim kriterijima za nuspojave Nacionalnog instituta za rak (NCI-CTCAE) verzije 5.0 ili odgovarajućom RTOG ocjenom.
11. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 6, pri čemu upotreba sprječava eskalaciju kožne nuspojave sa stupnja 0 na stupanj 1, 2, 3 ili 4, kako je definirano Zajedničkim terminološkim kriterijima za nuspojave Nacionalnog instituta za rak (NCI-CTCAE) verzije 5.0 ili odgovarajućom RTOG ocjenom.
12. Sastav za lokalnu primjenu za upotrebu prema patentnom zahtjevu 6, pri čemu upotreba sprječava eskalaciju kožne nuspojave sa stupnja 1 na stupanj 2, 3 ili 4, kako je definirano Zajedničkim terminološkim kriterijima za nuspojave Nacionalnog instituta za rak (NCI-CTCAE) verzije 5.0 ili odgovarajućom RTOG ocjenom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804235P | 2019-02-12 | 2019-02-12 | |
| EP20756229.9A EP3923911B1 (en) | 2019-02-12 | 2020-02-11 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
| PCT/IB2020/051073 WO2020165755A1 (en) | 2019-02-12 | 2020-02-11 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231241T1 true HRP20231241T1 (hr) | 2024-02-16 |
Family
ID=72044789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231241TT HRP20231241T1 (hr) | 2019-02-12 | 2020-02-11 | Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11439648B2 (hr) |
| EP (1) | EP3923911B1 (hr) |
| JP (1) | JP2022519675A (hr) |
| KR (1) | KR102534457B1 (hr) |
| CN (1) | CN113382717A (hr) |
| AU (1) | AU2020220895B9 (hr) |
| BR (1) | BR112021015137A2 (hr) |
| CA (1) | CA3127175C (hr) |
| ES (1) | ES2952251T3 (hr) |
| HR (1) | HRP20231241T1 (hr) |
| HU (1) | HUE063091T2 (hr) |
| IL (1) | IL285560B2 (hr) |
| MX (1) | MX2021009535A (hr) |
| PL (1) | PL3923911T3 (hr) |
| RS (1) | RS64618B1 (hr) |
| WO (1) | WO2020165755A1 (hr) |
| ZA (1) | ZA202106581B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022136912A1 (en) * | 2020-12-24 | 2022-06-30 | Lutris Pharma Ltd. | Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions |
| WO2023275620A2 (en) * | 2021-07-02 | 2023-01-05 | Lutris Pharma Ltd. | Use of isoquinoline-1,5-diamines for wound healing |
| CN118139621A (zh) * | 2021-09-30 | 2024-06-04 | 北京大学 | 一种对红系前体细胞或成红细胞进行扩增的方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753612A (en) | 1992-10-27 | 1998-05-19 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| SG10201608813PA (en) * | 2008-03-17 | 2016-12-29 | Ambit Biosciences Corp | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| WO2011117381A1 (en) * | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| TWI611053B (zh) | 2012-02-27 | 2018-01-11 | 曾宇鳳 | 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良 |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| US20170100345A1 (en) * | 2014-05-06 | 2017-04-13 | The Regents Of The University Of California | Wound healing using braf inhibitors |
| EP3426254B1 (en) * | 2016-03-10 | 2023-06-07 | Lutris Pharma Ltd. | Use of braf inhibitors for treating cutaneous reactions |
| AU2018311538B2 (en) * | 2017-07-29 | 2021-03-25 | Lutris Pharma Ltd. | Novel BRaf inhibitors and use thereof for treatment of cutaneous reactions |
| EP3664849B1 (en) * | 2017-08-08 | 2024-05-15 | Memorial Sloan Kettering Cancer Center | Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor |
-
2020
- 2020-02-11 HR HRP20231241TT patent/HRP20231241T1/hr unknown
- 2020-02-11 IL IL285560A patent/IL285560B2/en unknown
- 2020-02-11 HU HUE20756229A patent/HUE063091T2/hu unknown
- 2020-02-11 RS RS20230855A patent/RS64618B1/sr unknown
- 2020-02-11 WO PCT/IB2020/051073 patent/WO2020165755A1/en active Application Filing
- 2020-02-11 EP EP20756229.9A patent/EP3923911B1/en active Active
- 2020-02-11 MX MX2021009535A patent/MX2021009535A/es unknown
- 2020-02-11 PL PL20756229.9T patent/PL3923911T3/pl unknown
- 2020-02-11 BR BR112021015137-0A patent/BR112021015137A2/pt unknown
- 2020-02-11 JP JP2021545958A patent/JP2022519675A/ja active Pending
- 2020-02-11 CA CA3127175A patent/CA3127175C/en active Active
- 2020-02-11 KR KR1020217029012A patent/KR102534457B1/ko active IP Right Grant
- 2020-02-11 CN CN202080012207.4A patent/CN113382717A/zh active Pending
- 2020-02-11 AU AU2020220895A patent/AU2020220895B9/en active Active
- 2020-02-11 ES ES20756229T patent/ES2952251T3/es active Active
-
2021
- 2021-07-23 US US17/384,221 patent/US11439648B2/en active Active
- 2021-09-07 ZA ZA2021/06581A patent/ZA202106581B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE063091T2 (hu) | 2024-01-28 |
| IL285560A (en) | 2021-09-30 |
| AU2020220895A1 (en) | 2021-08-12 |
| EP3923911A4 (en) | 2022-11-09 |
| CN113382717A (zh) | 2021-09-10 |
| BR112021015137A2 (pt) | 2021-09-28 |
| WO2020165755A1 (en) | 2020-08-20 |
| US20210346389A1 (en) | 2021-11-11 |
| IL285560B2 (en) | 2024-04-01 |
| MX2021009535A (es) | 2022-10-10 |
| CA3127175C (en) | 2023-06-27 |
| RS64618B1 (sr) | 2023-10-31 |
| AU2020220895B2 (en) | 2022-11-17 |
| KR20210126665A (ko) | 2021-10-20 |
| JP2022519675A (ja) | 2022-03-24 |
| EP3923911A1 (en) | 2021-12-22 |
| ZA202106581B (en) | 2022-09-28 |
| IL285560B1 (en) | 2023-12-01 |
| CA3127175A1 (en) | 2020-08-20 |
| EP3923911C0 (en) | 2023-07-12 |
| ES2952251T3 (es) | 2023-10-30 |
| KR102534457B1 (ko) | 2023-05-18 |
| PL3923911T3 (pl) | 2023-12-27 |
| US11439648B2 (en) | 2022-09-13 |
| EP3923911B1 (en) | 2023-07-12 |
| AU2020220895B9 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231241T1 (hr) | Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| JP2011116787A5 (hr) | ||
| MX2020012595A (es) | Composiciones farmaceuticas topicas. | |
| RU2014152445A (ru) | Композиции на основе диклофенака | |
| RU2015149680A (ru) | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| JP2015522049A5 (hr) | ||
| RU2010107892A (ru) | Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их | |
| EA201492091A1 (ru) | Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину | |
| MX2007000967A (es) | Composiciones de risedronato y metodos para su uso. | |
| BRPI0716214A2 (pt) | Composições farmacêuticas para o tratamento de infecções fúngicas. | |
| US20180369174A1 (en) | Methods and compositions for treating peripheral neuropathy | |
| MX2013002649A (es) | Agente terapeutico contra el dolor. | |
| JP2015081244A (ja) | ニキビ治療用医薬組成物 | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 | |
| RU2021126784A (ru) | Применение композиций на основе ингибитора braf для наружнего применения для лечения лучевого дерматита | |
| EP1670464B1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| JPWO2020165755A5 (hr) | ||
| Aoki et al. | Cerebroprotective action of a Na+/Ca2+ channel blocker NS-7: I. Effect on the cerebral infarction and edema at the acute stage of permanent middle cerebral artery occlusion in rats | |
| NZ606177A (en) | Compositions for the treatment of actinic keratosis | |
| JP3338877B2 (ja) | 掻痒性皮膚疾患用噴霧剤 | |
| CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| JP7271163B2 (ja) | 外用組成物 |